Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease

NCT ID: NCT00855855

Last Updated: 2022-04-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20830 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-02-28

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To monitor the occurrence of invasive Hib disease over time and to determine product-specific rates of invasive Hib disease within the monitored population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of the study is to conduct surveillance for Hib disease.

Prospective active population-based surveillance for invasive Hib disease, conducted by the Center for Disease Control and Prevention (CDC) Active Bacterial Core (ABCs) program within geographic regions currently representing 12% of the US population, will provide Hib case-occurrence (numerator) data.

The ABCs program and the National Center for Health Statistics will provide annual estimates of the number of persons under surveillance, by age group, within the ABCs catchment area.

Ongoing telephone sample surveys, conducted by M/A/R/C, a national sampling organization, will provide brand-specific vaccine exposure data by age group within the ABCs program catchment area at appropriate pre-specified intervals (denominator data).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Haemophilus Infections Diphtheria Tetanus Polio Pertussis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hib vaccine

Participants has received at least one dose of an Hib vaccine

DTaP-IPV/Hib

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DTaP-IPV/Hib

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pentacel® ActHIB™ Comvax™ PedvaxHIB™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Residence within the geographic scope of Active Bacterial Core surveillance (ABCs) during the period of surveillance
* Aged 0 through 59 months (prior to 5th birthday) on the day of inclusion for Hib disease surveillance and 2 through 23 months (prior to 2nd birthday) for Hib vaccine brand usage survey.
* 2009-2014 calendar years inclusive.
* For the Hib vaccine usage survey, agreement to complete the required survey.

Exclusion Criteria

Not applicable.
Maximum Eligible Age

59 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sanofi Pasteur, a Sanofi Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Sanofi Pasteur Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Albany, California, United States

Site Status

Martinez, California, United States

Site Status

San Francisco, California, United States

Site Status

Applewood, Colorado, United States

Site Status

Aurora, Colorado, United States

Site Status

Brighton, Colorado, United States

Site Status

Castle Rock, Colorado, United States

Site Status

Denver, Colorado, United States

Site Status

Hartford, Connecticut, United States

Site Status

Adamsville, Georgia, United States

Site Status

Auburn, Georgia, United States

Site Status

Canton, Georgia, United States

Site Status

Carrollton, Georgia, United States

Site Status

Cartersville, Georgia, United States

Site Status

Conyers, Georgia, United States

Site Status

Covington, Georgia, United States

Site Status

Cumming, Georgia, United States

Site Status

Dallas, Georgia, United States

Site Status

Decatur, Georgia, United States

Site Status

Douglasville, Georgia, United States

Site Status

Fayetteville, Georgia, United States

Site Status

Good Hope, Georgia, United States

Site Status

Griffin, Georgia, United States

Site Status

Hampton, Georgia, United States

Site Status

Jasper, Georgia, United States

Site Status

Jonesboro, Georgia, United States

Site Status

Marietta, Georgia, United States

Site Status

Newnan, Georgia, United States

Site Status

Annapolis, Maryland, United States

Site Status

Saint Paul, Minnesota, United States

Site Status

Santa Fe, New Mexico, United States

Site Status

Albany, New York, United States

Site Status

Amsterdam, New York, United States

Site Status

Avon, New York, United States

Site Status

Batavia, New York, United States

Site Status

Bellona, New York, United States

Site Status

Canandaigua, New York, United States

Site Status

Catskill, New York, United States

Site Status

Chatham, New York, United States

Site Status

Geneva, New York, United States

Site Status

Mechanicville, New York, United States

Site Status

Medina, New York, United States

Site Status

Palmyra, New York, United States

Site Status

Rochester, New York, United States

Site Status

Schenectady, New York, United States

Site Status

Schoharie, New York, United States

Site Status

Troy, New York, United States

Site Status

Salem, Oregon, United States

Site Status

Ashland City, Tennessee, United States

Site Status

Charlotte, Tennessee, United States

Site Status

Chattanooga, Tennessee, United States

Site Status

Franklin, Tennessee, United States

Site Status

Gallatin, Tennessee, United States

Site Status

Knoxville, Tennessee, United States

Site Status

Lebanon, Tennessee, United States

Site Status

Memphis, Tennessee, United States

Site Status

Murfreesboro, Tennessee, United States

Site Status

Nashville, Tennessee, United States

Site Status

Springfield, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

M5A15

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.